CarsonAllaria Wealth Management Ltd. Cuts Stock Holdings in GSK plc (NYSE:GSK)

CarsonAllaria Wealth Management Ltd. lowered its position in GSK plc (NYSE:GSK) by 10.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,868 shares of the pharmaceutical company’s stock after selling 461 shares during the period. CarsonAllaria Wealth Management Ltd.’s holdings in GSK were worth $149,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in GSK. JTC Employer Solutions Trustee Ltd lifted its position in shares of GSK by 71.3% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after buying an additional 8,800,822 shares in the last quarter. Fisher Asset Management LLC boosted its position in GSK by 10.8% in the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after purchasing an additional 1,465,165 shares during the last quarter. Primecap Management Co. CA grew its stake in GSK by 0.3% in the 4th quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock valued at $448,032,000 after purchasing an additional 30,600 shares during the period. Mondrian Investment Partners LTD increased its position in shares of GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after purchasing an additional 1,512,442 shares during the last quarter. Finally, Provident Trust Co. raised its stake in shares of GSK by 53.6% during the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after purchasing an additional 1,297,385 shares during the period. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GSK shares. Jefferies Financial Group raised their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Citigroup raised GSK to a “strong-buy” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Stock Performance

Shares of NYSE:GSK traded up $0.08 during trading on Tuesday, hitting $41.60. 1,646,540 shares of the company were exchanged, compared to its average volume of 3,559,768. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The stock has a 50 day moving average of $39.75 and a 200 day moving average of $41.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.58. The company has a market cap of $86.22 billion, a PE ratio of 15.07, a P/E/G ratio of 1.32 and a beta of 0.64.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.3843 per share. This represents a $1.54 dividend on an annualized basis and a yield of 3.70%. The ex-dividend date is Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is presently 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.